Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nagase Viita, formerly known as Hayashibara, is a leading Japanese biotechnology company specializing in the production of functional carbohydrates and bioactive ingredients through advanced enzymatic technology. The company is a global leader in the manufacture of high-purity trehalose, pullulan, and stabilized vitamin C (AA2G), which are widely used in the pharmaceutical, cosmetic, and food sectors. Their expertise extends to the production of pharmaceutical-grade excipients and active ingredients, including human interferon-alpha. Since becoming a wholly-owned subsidiary of Nagase & Co., the company has integrated its operations to focus on sustainable life science solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hayashibara International.